Course of Pharmaceutical Sciences, Graduate School of Biomedical Sciences, Nagasaki University, 1-14 Bunkyo-machi, Nagasaki 852-8521, Japan; Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt.
Course of Pharmaceutical Sciences, Graduate School of Biomedical Sciences, Nagasaki University, 1-14 Bunkyo-machi, Nagasaki 852-8521, Japan.
Talanta. 2018 Apr 1;180:323-328. doi: 10.1016/j.talanta.2017.12.023. Epub 2017 Dec 12.
Pre-column derivatization with fluorescence labeling reagents involves many problems including crowded chromatograms, possibility of the introduction of analytical errors, and poor selectivity. Herein we report a novel purification tag/fluorophore dual labeling approach based on a multi-component reaction to solve this major problem. Glyoxylic acid was recently identified as an early biomarker for diabetes, thus it was selected as a model analyte for our new dual labeling approach. Using the multi-component Petasis reaction, we could introduce a fluorophore (1-pyreneboronic acid, 1-PyBA) and a purification tag (taurine) to our target analyte (glyoxylic acid) in one step reaction. Using taurine as the amine reactant in Petasis reaction leads to the formation of a reaction product with a terminal sulfonic acid group which can be selectively retained on an anion exchange sorbent allowing excess fluorescent 1-PyBA reagent and its fluorescent decomposition products to be washed away. Then, quantification of the formed analyte-fluorophore-purification tag adduct was carried out by a simple isocratic HPLC-fluorescence detection method. The newly developed technique allowed highly selective, very rapid and efficient determination of glyoxylic acid in human serum eliminating endogenous components and excess reagent interference. Glyoxylic acid was determined in serum at a final concentration down to 30nM (600 fmol/injection) with good recovery (87.0%), accuracy (- 2.2 to 9.2) and precision (%RSD ≤ 8.7).
柱前衍生化与荧光标记试剂有关,包括色谱峰拥挤、分析误差的可能性以及选择性差等诸多问题。在此,我们报告了一种基于多组分反应的新型纯化标签/荧光团双重标记方法,以解决这一主要问题。乙醛酸最近被确定为糖尿病的早期生物标志物,因此被选为我们新的双重标记方法的模型分析物。通过多组分 Petasis 反应,我们可以在一步反应中向目标分析物(乙醛酸)中引入荧光团(1-芘硼酸,1-PyBA)和纯化标签(牛磺酸)。在 Petasis 反应中使用牛磺酸作为胺反应物,会导致形成末端磺酸基的反应产物,该产物可以选择性地保留在阴离子交换吸附剂上,从而将过量的荧光 1-PyBA 试剂及其荧光分解产物洗掉。然后,通过简单的等度 HPLC-荧光检测方法对形成的分析物-荧光团-纯化标签加合物进行定量。新开发的技术允许对人血清中的乙醛酸进行高度选择性、快速和有效的测定,消除内源性成分和过量试剂的干扰。在最终浓度低至 30nM(600fmol/进样)的血清中可以测定乙醛酸,回收率良好(87.0%),准确性(-2.2 至 9.2)和精密度(%RSD≤8.7)。